DMPA-SC self-injection resources

Self-injection with DMPA-SC (brand name Sayana® Press) has the potential to reduce access-related barriers for women, increase contraceptive continuation rates, and enhance women’s autonomy. There is clear evidence that women—including women in low-resource settings—can self-administer DMPA-SC safely and effectively, and that they like doing so.

An increasing number of countries worldwide are adding DMPA-SC to their contraceptive method mix and including self-injection as one option women can choose. Senegal and Uganda plan to scale up self-injection, and the Democratic Republic of the Congo, Ghana, Malawi, and Nigeria are in early stages of introducing the practice. And PATH’s Self-Injection Best Practices initiative in Uganda is identifying self-injection program approaches that work, informing policy and practice worldwide.

For more information, visit www.path.org/dmpa-sc, sign up for our newsletter, or email FPoptions@path.org.

Overview and training resources

• Self-injected subcutaneous DMPA: A new frontier in advancing contraceptive access and use for women
• Self-injection: Empowering Women Who Want to "Stick" with Contraception
• Self-Injection Best Practices web page
• DMPA-SC training materials for providers and self-injection clients

Research briefs

• DMPA-SC Self-injection Best Practices project brief
• Self-injection feasibility and acceptability brief
• DMPA-SC self-injection continuation research brief

*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate.
Sayana Press is a registered trademark of Pfizer Inc. Uniject is a trademark of BD.